NCT03770494 2025-11-04
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
Eli Lilly and Company
BioNTech SE
Memorial Sloan Kettering Cancer Center
Gilead Sciences
Debiopharm International SA
Dana-Farber Cancer Institute
Ipsen
Eli Lilly and Company
Hoffmann-La Roche
Eli Lilly and Company
Bristol-Myers Squibb
Pfizer